Johnson & Johnson CEO stepping down in January

35
9
Favorite

Johnson & Johnson CEO stepping down in January

FOX Business2021-08-20

Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role. Johnson & Johnson CEO Alex Gorskywill step down in January, the company announced...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（9）

shshsh999
·2021-08-20
Hmm
Reply
Like
Report
AlvinTham
·2021-08-20
Comment and like pls, thanks!
Reply
Like
Report
Euginelai
·2021-08-20
Ok
Reply
3
Report
Fold Replies
- AlvinTham:
  Connent and like pls, thanks!
  2021-08-20
  Reply
  Report
theunmouse
·2021-08-20
Aiyo
Reply
5
Report
Yandaoxiang
·2021-08-20
Who’s next?
Reply
4
Report
ApplePL
·2021-08-20
Pls like n comment. Will revert.thx
Reply
5
Report
Fold Replies
- Euginelai:
  ok
  2021-08-20
  Reply
  Report
ZhaoYingying
·2021-08-20
Like pls
Reply
5
Report
Fold Replies
- Faithc:
  Done
  2021-08-20
  Reply
  Report
jijimo
·2021-08-20
Like my post !
Reply
14
Report
Fold Replies
- james_l:
  sure
  2021-08-20
  Reply
  Report
- RC_ADRIC:
  ok
  2021-08-20
  Reply
  Report
hitithard
·2021-08-20
Ok
Reply
6
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1133561437?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-20 15:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133561437","market":"us","top_or_hot":-1,"title":"Johnson & Johnson CEO stepping down in January","media":"FOX Business","content":"<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Source Link</a>\n\n</div>\n","source":"lsy1602566126337","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","article_id":"1133561437","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","pubTimestamp":1629445627,"sourceInfo":{"source_id":"lsy1602566126337","name":"FOX Business"},"weMediaInfo":null,"summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","collect":0,"end_time":0,"defaultTopTitle":"foxbusiness.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"强生CEO一月卸任","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":836964212,"gmtCreate":1629448228636,"gmtModify":1676530044535,"author":{"id":"3581559287302283","authorId":"3581559287302283","name":"shshsh999","avatar":"https://static.tigerbbs.com/9d90e2141ae1f9fb485478e3c1cc3f75","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581559287302283","authorIdStr":"3581559287302283"},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836964212","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":836981078,"gmtCreate":1629447387994,"gmtModify":1676530044058,"author":{"id":"3563561143098282","authorId":"3563561143098282","name":"AlvinTham","avatar":"https://static.tigerbbs.com/845cfac0b817ce044b5bb49a395c4ca7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3563561143098282","authorIdStr":"3563561143098282"},"htmlText":"Comment and like pls, thanks!","listText":"Comment and like pls, thanks!","text":"Comment and like pls, thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836981078","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":836915199,"gmtCreate":1629446976311,"gmtModify":1676530043914,"author":{"id":"3577190611611615","authorId":"3577190611611615","name":"Euginelai","avatar":"https://static.tigerbbs.com/f372cf5db2ff096891b722c46529864e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577190611611615","authorIdStr":"3577190611611615"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/836915199","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5589246,"gmtCreate":1629447409421,"gmtModify":1663232656147,"authorId":3563561143098282,"author":{"id":3563561143098282,"idStr":"3563561143098282","authorId":3563561143098282,"name":"AlvinTham","avatar":"https://static.tigerbbs.com/845cfac0b817ce044b5bb49a395c4ca7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":836915199,"type":1,"supId":0,"prevId":0,"content":"Connent and like pls, thanks!","text":"Connent and like pls, thanks!","html":"Connent and like pls, thanks!"}],"langContent":"EN"},{"id":836916878,"gmtCreate":1629446676694,"gmtModify":1676530043882,"author":{"id":"3572018203797244","authorId":"3572018203797244","name":"theunmouse","avatar":"https://static.tigerbbs.com/c336181da66212b3d13c0ea59b6f69b5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572018203797244","authorIdStr":"3572018203797244"},"htmlText":"Aiyo","listText":"Aiyo","text":"Aiyo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836916878","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":836916325,"gmtCreate":1629446673367,"gmtModify":1676530043873,"author":{"id":"3572095880096095","authorId":"3572095880096095","name":"Yandaoxiang","avatar":"https://static.tigerbbs.com/6330cd1176a93a8c564f8047fd53d835","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3572095880096095","authorIdStr":"3572095880096095"},"htmlText":"Who’s next?","listText":"Who’s next?","text":"Who’s next?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836916325","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":836918931,"gmtCreate":1629446596423,"gmtModify":1676530043851,"author":{"id":"3581735199167645","authorId":"3581735199167645","name":"ApplePL","avatar":"https://static.tigerbbs.com/0aa8f389e191dba5ddcc664bc53af5a4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581735199167645","authorIdStr":"3581735199167645"},"htmlText":"Pls like n comment. Will revert.thx","listText":"Pls like n comment. Will revert.thx","text":"Pls like n comment. Will revert.thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/836918931","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5589175,"gmtCreate":1629446985321,"gmtModify":1631896339856,"authorId":3577190611611615,"author":{"id":3577190611611615,"idStr":"3577190611611615","authorId":3577190611611615,"name":"Euginelai","avatar":"https://static.tigerbbs.com/f372cf5db2ff096891b722c46529864e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":836918931,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":836913025,"gmtCreate":1629446310067,"gmtModify":1676530043801,"author":{"id":"3577155247763320","authorId":"3577155247763320","name":"ZhaoYingying","avatar":"https://static.tigerbbs.com/b86f603c032bb4185ad17dff4bc5cb95","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577155247763320","authorIdStr":"3577155247763320"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/836913025","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5589186,"gmtCreate":1629447046381,"gmtModify":1663232655438,"authorId":3577501750554592,"author":{"id":3577501750554592,"idStr":"3577501750554592","authorId":3577501750554592,"name":"Faithc","avatar":"https://static.tigerbbs.com/e05208519e0467a3e2353dfaeb49b873","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":836913025,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":836935714,"gmtCreate":1629445820438,"gmtModify":1676530043667,"author":{"id":"3577075923922212","authorId":"3577075923922212","name":"jijimo","avatar":"https://static.tigerbbs.com/22bac6d28b6513739fc962def9c071bd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577075923922212","authorIdStr":"3577075923922212"},"htmlText":"Like my post !&nbsp;","listText":"Like my post !&nbsp;","text":"Like my post !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/836935714","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5589946,"gmtCreate":1629451726203,"gmtModify":1663232658130,"authorId":3563436875655076,"author":{"id":3563436875655076,"idStr":"3563436875655076","authorId":3563436875655076,"name":"james_l","avatar":"https://static.tigerbbs.com/7960ea5c640db331ff2de0da32f6a611","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":836935714,"type":1,"supId":0,"prevId":0,"content":"sure","text":"sure","html":"sure"},{"id":5589058,"gmtCreate":1629446051653,"gmtModify":1663232653042,"authorId":3574743613224710,"author":{"id":3574743613224710,"idStr":"3574743613224710","authorId":3574743613224710,"name":"RC_ADRIC","avatar":"https://static.tigerbbs.com/ff53482947c23ec372fe52411816b015","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":836935714,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":836935180,"gmtCreate":1629445772240,"gmtModify":1676530043657,"author":{"id":"3570063321997588","authorId":"3570063321997588","name":"hitithard","avatar":"https://static.tigerbbs.com/309ce7b357018aa7b946332c2fe8725c","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3570063321997588","authorIdStr":"3570063321997588"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836935180","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","pubTimestamp":1629445627,"share":"https://ttm.financial/m/news/1133561437?lang=&edition=fundamental","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p>\n<p><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p>\n<p>Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p>\n<p>Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p>\n<table>\n <thead>\n  <tr>\n   <th>Ticker</th>\n   <th>Security</th>\n   <th>Last</th>\n   <th>Change</th>\n   <th>Change %</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>JNJ</td>\n   <td>JOHNSON &amp; JOHNSON</td>\n   <td>178.57</td>\n   <td>+1.38</td>\n   <td>+0.78%</td>\n  </tr>\n  <tr></tr>\n </tbody>\n</table>\n<p>Duato said he was \"honored\" by the appointment.</p>\n<p>\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p>\n<p>Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p>\n<p>\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p>\n<p>Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p>\n<p>Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p>\n<p>Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p>\n<p>He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p>\n<p>Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p>\n<p>\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p>\n<p>The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p>\n<p></p>\n<ul></ul>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down><strong>FOX Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced...</p>\n\n<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":35,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}